SHH · 688235.SS
BeOne Medicines Ltd. Class A
CN¥255.62+CN¥1.93 (+0.76%)
BeOne Medicines Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
Loading market information…
HKSE · 1276.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s forward annual dividend is HK$0.23 per share, paid annual. The forward yield is 0.44% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s next earnings report is currently expected on Apr 19, 2027, with estimated earnings per share of HK$0.38. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$7.72B+13.3% vs estimate |
| Q4 2024 | Mar 30, 2025 | HK$0.29+0.1% vs estimate | HK$8.42B+23.66% vs estimate |
|---|
| Q3 2024 | Oct 24, 2024 | HK$0.20-2.09% vs estimate | HK$7.19B+0.52% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥255.62+CN¥1.93 (+0.76%)
BeOne Medicines Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
₩190,700+₩1,400 (+0.74%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 20.23% below the high.
HK$32.96-HK$0.12 (-0.36%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 25.46% below the high.
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
¥3,029+¥40 (+1.34%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.4% below the high.
HK$436.80-HK$1.00 (-0.23%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
CN¥32.44+CN¥0.33 (+1.03%)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 51.31% below the high.
CN¥29.89+CN¥0.05 (+0.17%)
Shanghai Junshi Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.79% below the high.
